Aprotinin in cardiac surgery
- PMID: 16509811
- DOI: 10.1586/14779072.4.2.151
Aprotinin in cardiac surgery
Abstract
Aprotinin is a naturally occurring serine protease inhibitor that is being used with increasing frequency in cardiac surgery and beyond to reduce blood loss and the need for perioperative blood transfusion. Through inhibition of serine proteases such as plasmin, aprotinin significantly reduces fibrinolysis, thereby aiding hemostasis during surgical procedures. In addition, aprotinin interacts with other factors in the coagulation and fibrinolytic cascade, creating a hemostatic balance, without increasing the risk of thrombosis. These proven benefits are supplemented by the anti-inflammatory properties of aprotinin, which may help curb some of the deleterious effects of cardiopulmonary bypass. This article will review the discovery of aprotinin, its mechanism of action, dosing and adverse effects, and highlight the major recent trials demonstrating its efficacy.
Similar articles
-
Con: Aprotinin should not be used in cardiac surgery with cardiopulmonary bypass.J Cardiothorac Vasc Anesth. 2007 Apr;21(2):302-4. doi: 10.1053/j.jvca.2007.01.002. J Cardiothorac Vasc Anesth. 2007. PMID: 17418754 No abstract available.
-
Aprotinin: antifibrinolytic and anti-inflammatory mechanisms of action in cardiac surgery with cardiopulmonary bypass.Dynamics. 2002 Fall;13(3):16-23. Dynamics. 2002. PMID: 12640841 Review.
-
Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action.Anesth Analg. 2007 Oct;105(4):949-62. doi: 10.1213/01.ane.0000281936.04102.9f. Anesth Analg. 2007. PMID: 17898372 Review.
-
Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction.Semin Cardiothorac Vasc Anesth. 2006 Jun;10(2):132-42. doi: 10.1177/1089253206288997. Semin Cardiothorac Vasc Anesth. 2006. PMID: 16959740 Review.
-
[Aprotinin (Antilysin Spofa)--its effect on decreasing hemorrhage in the postoperative period in hip arthroplasty].Acta Chir Orthop Traumatol Cech. 2001;68(5):311-4. Acta Chir Orthop Traumatol Cech. 2001. PMID: 11759474 Clinical Trial. Czech.
Cited by
-
Fibrinogen and Prothrombin Complex Concentrate: The Importance of the Temporal Sequence-A Post-Hoc Analysis of Two Randomized Controlled Trials.J Clin Med. 2024 Nov 25;13(23):7137. doi: 10.3390/jcm13237137. J Clin Med. 2024. PMID: 39685596 Free PMC article.
-
A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.Drug Saf. 2008;31(3):217-30. doi: 10.2165/00002018-200831030-00003. Drug Saf. 2008. PMID: 18302446 Review.
-
Clinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularization.Surg Today. 2012 Apr;42(4):334-41. doi: 10.1007/s00595-011-0012-9. Epub 2011 Nov 10. Surg Today. 2012. PMID: 22068670 Clinical Trial.
-
Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature.PLoS One. 2011 Feb 22;6(2):e17229. doi: 10.1371/journal.pone.0017229. PLoS One. 2011. PMID: 21364954 Free PMC article.
-
The effect of L-arginine and aprotinin on intestinal ischemia-reperfusion injury.J Gastrointest Surg. 2007 Mar;11(3):247-55. doi: 10.1007/s11605-007-0102-6. J Gastrointest Surg. 2007. PMID: 17458594
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical